A detailed history of E Fund Management Co., Ltd. transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 35,232 shares of FOLD stock, worth $353,024. This represents 0.03% of its overall portfolio holdings.

Number of Shares
35,232
Previous 42,548 17.19%
Holding current value
$353,024
Previous $603,000 31.18%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$11.43 - $14.24 $83,621 - $104,179
-7,316 Reduced 17.19%
35,232 $415,000
Q4 2023

Feb 06, 2024

BUY
$9.97 - $14.52 $61,524 - $89,602
6,171 Added 16.96%
42,548 $603,000
Q3 2023

Nov 13, 2023

BUY
$11.78 - $13.86 $17,787 - $20,928
1,510 Added 4.33%
36,377 $442,000
Q2 2023

Aug 11, 2023

BUY
$10.72 - $13.3 $11,888 - $14,749
1,109 Added 3.29%
34,867 $438,000
Q1 2023

May 11, 2023

SELL
$10.91 - $13.54 $26,216 - $32,536
-2,403 Reduced 6.65%
33,758 $374,000
Q4 2022

Feb 14, 2023

SELL
$9.89 - $12.7 $54,899 - $70,497
-5,551 Reduced 13.31%
36,161 $442,000
Q3 2022

Nov 14, 2022

SELL
$9.82 - $12.75 $105,339 - $136,769
-10,727 Reduced 20.46%
41,712 $435,000
Q2 2022

Aug 15, 2022

BUY
$6.23 - $11.12 $146,803 - $262,031
23,564 Added 81.61%
52,439 $563,000
Q1 2022

May 12, 2022

BUY
$7.89 - $12.48 $94,727 - $149,834
12,006 Added 71.17%
28,875 $273,000
Q4 2021

Feb 11, 2022

BUY
$9.82 - $12.44 $10,782 - $13,659
1,098 Added 6.96%
16,869 $195,000
Q3 2021

Nov 12, 2021

BUY
$8.74 - $11.84 $25,424 - $34,442
2,909 Added 22.62%
15,771 $151,000
Q1 2021

May 12, 2021

BUY
$9.2 - $23.86 $118,330 - $306,887
12,862 New
12,862 $127,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.81B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.